How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide

False-susceptible phenotypic drug-susceptibility testing (DST) results for pyrazinamide due to mutations with MICs close to the critical concentration (CC) confound the classification of pncA resistance mutations, leading to an underestimate of the specificity of genotypic DST. This could be minimiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Köser, Claudio U., Cirillo, Daniela M., Miotto, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Mechanisms of Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449218/
https://www.ncbi.nlm.nih.gov/pubmed/32571824
http://dx.doi.org/10.1128/AAC.01003-20
_version_ 1783574617555730432
author Köser, Claudio U.
Cirillo, Daniela M.
Miotto, Paolo
author_facet Köser, Claudio U.
Cirillo, Daniela M.
Miotto, Paolo
author_sort Köser, Claudio U.
collection PubMed
description False-susceptible phenotypic drug-susceptibility testing (DST) results for pyrazinamide due to mutations with MICs close to the critical concentration (CC) confound the classification of pncA resistance mutations, leading to an underestimate of the specificity of genotypic DST. This could be minimized by basing treatment decisions on well-understood mutations and by adopting an area of technical uncertainty for phenotypic DST rather than only testing the CC, as is current practice for the Mycobacterium tuberculosis complex.
format Online
Article
Text
id pubmed-7449218
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-74492182020-09-09 How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide Köser, Claudio U. Cirillo, Daniela M. Miotto, Paolo Antimicrob Agents Chemother Mechanisms of Resistance False-susceptible phenotypic drug-susceptibility testing (DST) results for pyrazinamide due to mutations with MICs close to the critical concentration (CC) confound the classification of pncA resistance mutations, leading to an underestimate of the specificity of genotypic DST. This could be minimized by basing treatment decisions on well-understood mutations and by adopting an area of technical uncertainty for phenotypic DST rather than only testing the CC, as is current practice for the Mycobacterium tuberculosis complex. American Society for Microbiology 2020-08-20 /pmc/articles/PMC7449218/ /pubmed/32571824 http://dx.doi.org/10.1128/AAC.01003-20 Text en Copyright © 2020 Köser et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Mechanisms of Resistance
Köser, Claudio U.
Cirillo, Daniela M.
Miotto, Paolo
How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title_full How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title_fullStr How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title_full_unstemmed How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title_short How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
title_sort how to optimally combine genotypic and phenotypic drug susceptibility testing methods for pyrazinamide
topic Mechanisms of Resistance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449218/
https://www.ncbi.nlm.nih.gov/pubmed/32571824
http://dx.doi.org/10.1128/AAC.01003-20
work_keys_str_mv AT koserclaudiou howtooptimallycombinegenotypicandphenotypicdrugsusceptibilitytestingmethodsforpyrazinamide
AT cirillodanielam howtooptimallycombinegenotypicandphenotypicdrugsusceptibilitytestingmethodsforpyrazinamide
AT miottopaolo howtooptimallycombinegenotypicandphenotypicdrugsusceptibilitytestingmethodsforpyrazinamide

Ejemplares similares